Reading the tape
NASDAQ: CYCN
Cyclerion Therapeutics, Inc.
Healthcare · Biotechnology
Market Cap
$14.12M
52w High
$8.48
52w Low
$1.03
P/E
-2.98
Volume
78.00K
Outstanding Shares
4.33M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 9.76%Revenue (TTM): 3.7%FCF (TTM): 23.52%P/S: 25th pct
What changed
The stock rose 9.76% over the last year. Revenue grew 3.7% over the trailing twelve months. Operating margin moved from -181.4% to -239.78%. Free cash flow grew 23.52% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -239.78%. A decisive move in revenue — currently up 3.7% — would be the clearest signal to resolve the ambiguity.
Company profile
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases.
CEORegina Graul
SectorHealthcare
IndustryBiotechnology
Employees1
IPO dateMar 18, 2019
Valuation
Forward P/E—
EV/EBITDA-0.17
Enterprise value$855.75K
Stock splits
May 16, 2023↓ Reverse
Every 20 shares became 1
Profitability & growth
Revenue growth-43.24%
Gross margin100%▲0.00%vs FY2024
Operating margin-239.78%▼32.18%vs FY2024
ROE-38.83%▼12.42%vs FY2024
Analyst consensus
RatingBuy
Target price—
2
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 5, 2026
Q2 FY26 · EPS est -$17.20 · Revenue est $875.23K
View